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ABSTRACT
Leukemic cells from Chronic Lymphocytic Leukemia (CLL) patients interact with 
stromal cells of the surrounding microenvironment. Mesenchymal Stromal Cells 
(MSCs) represent the main population in CLL marrow stroma, which may play a key 
role for disease support and progression. In this study we evaluated whether MSCs 
influence in vitro CLL cell survival. MSCs were isolated from the bone marrow of 46 CLL 
patients and were characterized by flow cytometry analysis. Following co-culture of 
MSCs and leukemic B cells, we demonstrated that MSCs were able to improve leukemic 
B cell viability, this latter being differently dependent from the signals coming from 
MSCs. In addition, we found that the co-culture of MSCs with leukemic B cells induced 
an increased production of IL-8, CCL4, CCL11, and CXCL10 chemokines.
As far as drug resistance is concerned, MSCs counteract the cytotoxic effect of 
Fludarabine/Cyclophosphamide administration in vivo, whereas they do not protect 
CLL cells from the apoptosis induced by the kinase inhibitors Bafetinib and Ibrutinib. 
The evidence that leukemic clones are conditioned by environmental stimuli suggest 
new putative targets for therapy in CLL patients.
INTRODUCTION
The accumulation of CD19+/CD5+/CD23+ B cells 
is a peculiar hallmark of B cell chronic lymphocytic 
leukemia (CLL) [1]. Despite a remarkable phenotypic 
and cytological homogeneity, CLL is characterized by 
extremely variable clinical course related to different 
prognostic factors including the mutational status of the 
immunoglobulin heavy-chain variable region (IgVH) [2-
4], expression of CD38 and ZAP70 markers [5, 6] and 
specific cytogenetic alterations [7-9]. Although leukemic 
cells show prolonged lifespan in the peripheral blood, 
secondary lymphoid organs and bone marrow (BM), 
they rapidly undergo spontaneous apoptosis in vitro 
[10, 11], suggesting that the leukemic B cells survival 
advantage could be attributed not only to intrinsic defects 
of apoptotic mechanisms but also to signals delivered by 
accessory cells at the sites of the disease activity. In tissue 
microenvironment, CLL B cells reside in close contact 
with T lymphocytes, stromal cells, mesenchymal stromal 
cells (MSCs), endothelial cells, follicular dendritic cells 
and macrophages. Interactions among these components 
of the microenvironment regulate the trafficking, survival, 
and proliferation of leukemic B cells in a way that depends 
both on direct cell-cell contact and/or on the exchange of 
soluble factors [12]. Moreover, once resident in stromal 
environment, CLL cells are protected from different 
therapeutic interventions [13-15].
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Among bone marrow stromal cells, MSCs show 
a bidirectional cross-talking with neoplastic B cells. 
Leukemic cells are supported by stromal cells and, in 
turn, are also able to activate and induce stromal cell to 
proliferate and release several mediators (i.e., CXCL12, 
CXCL13, CCL19 and CCL21) which sustain the ongoing 
process [16-18]. These interactions drive CLL B cells 
into tissue microenvironment, where malignant cells 
experience the survival and proliferation signals mediated 
by the B cell receptor (BCR) and other pathways [15]. 
Nevertheless, these complex cellular and molecular 
mechanisms are not yet completely defined. Although in 
healthy subjects MSCs represent a small fraction of the 
stromal cell population, immunohistochemistry studies 
performed in patients with several lymphoproliferative 
diseases showed that in situ αSMA+ mesenchymal 
stromal cells, which represent the in vivo counterpart of 
MSCs, are the dominant stromal cell population in CLL 
microenvironment [19]. These observations support 
a crucial role of MSCs on the mechanisms favoring 
malignant cells and disease progression in CLL.
In the last years, the modulation of tumor 
microenvironment is becoming a promising therapeutic 
strategy in CLL treatment, demonstrated by the use of 
an increased number of compounds (i.e. thalidomide, 
lenalidomide, plerixafor and natalizumab) [20, 21], 
affecting molecules involved in the compartimentalization 
of tumor cells. More recently, several small molecules 
have been developed to inhibit a variety of kinases in 
the BCR pathway, including Lyn, Syk, Btk and PI3K, 
which are crucial not only for the activation of multiple 
survival pathways (such as Akt, Erk, NF-kB) but also for 
chemokine-mediated migration and adhesion of B cells 
in the microenvironment [22]. Thus, the understanding 
of the interactions between CLL B cells and the 
microenvironment is mandatory to define more effective 
therapies for CLL. In this context, the main aim of this 
study was to investigate the in vitro impact of MSCs on 
CLL B cell survival in order to verify whether MSCs 
protect leukemic B cells from spontaneous apoptosis 
both at basal conditions and after in vivo Fludarabine and 
Cyclophosphamide containing regimen therapy. We also 
tested the effect of two kinase inhibitors, Bafetinib (dual 
BCR-Abl/Lyn inhibitor) and Ibrutinib (Btk inhibitor), 
known to reduce neoplastic B cell viability in vitro [23], 
on CLL B cells in presence of MSCs. Moreover, the 
investigation of soluble factors, mainly cytokines and 
chemokines, which could be involved in leukemic cell 
survival, was performed. Our data clearly demonstrated 
that MSCs display a pro-survival effect on leukemic B 
cells from CLL patients and that CLL clones displayed a 
variable degree of responsiveness to microenviromental 
stimuli, suggesting that same clones are dependent and 
other are independent from MSC pro-survival capability. 
This observation might be relevant in order to identify 
patients who may benefit of compounds targeting CLL 
microenvironment. 
RESULTS
Mesenchymal stromal cells from CLL patients 
display phenotypic profile and differentiation 
capability of MSCs from normal subjects
MSCs were obtained from the bone marrow of 46 
CLL patients by plastic adhesion as previously described 
[24, 25]. The adherent fraction leads to the formation of 
high proliferating spindle-shaped colonies, reaching the 
confluence in 30 days (Figure S1A). Flow cytometry 
analysis showed that MSCs were positive for CD90, 
CD73, CD105, and negative for CD14, CD34, CD45 
and CD31 (Figure S1B). MSC ability to differentiate 
in adipocytes and osteocytes was tested using specific 
conditioned media. Adipogenic differentiation was 
demonstrated by the detection of lipid vesicles in the 
cytoplasm of (pre)adipocytes, stained with Oil Red. 
Osteogenic differentiation was documented by the 
increased expression of mRNA coding for Core Binding 
Factor 1 (CBFA1) and the deposition of mineralized 
matrix, shown by the Von Kossa staining (Figure S1C). 
The cell adhesion, the immunophenotype and the 
differentiation ability of stromal cells generated in our 
cultures are in accordance to the criteria required for MSC 
characterization [26, 27]. 
MSCs from CLL patients support in vitro 
neoplastic B cell survival
We tested the effect of MSCs on the survival of 
leukemic B cells obtained from 30 CLL patients and 
normal B cells from 11 healthy donors. The assays were 
performed incubating leukemic and normal B lymphocytes 
in contact with a confluent layer of MSCs (20:1 ratio); 
CLL B cell viability was assessed at 3, 5 and 7 days using 
Annexin V staining. As shown in Figure 1A, leukemic 
B cells underwent apoptosis when cultured in medium 
alone; their survival was rescued following co-culture 
with MSCs (13.3%±13.2% CLL B cells in medium alone 
vs 59.2%±17.1% in presence of MSCs, after 7 days; p < 
0.0001). The same pro-survival effect was observed using 
both autologous and allogeneic MSCs (data not shown). In 
addition, MSCs displayed a higher protective effect with 
respect to the human stromal cell line HS-5 (59.2%±17.1% 
with MSCs vs 45.9% ± 15.4% with HS-5; p < 0.01). After 
7 days of culture, normal B cell survival with MSCs 
was 34.9%±15.7% vs 6.7%±4.3% in medium alone (p < 
0.001) (Figure 1B), pointing out that MSC display a major 
protective effect on malignant B cells. MSCs from healthy 
donors rescued CLL B cells from apoptosis as well as 
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MSCs from CLL patients (data not shown).
CLL clones show different sensitivity to MSC pro-
survival signals
Considering the heterogeneity of CLL B cell viability 
in the presence of MSCs (Figure 2A), we evaluated the 
PARP cleavage (generating an 89kDa fragment) as a 
marker of apoptosis in 27 CLL patient samples after 7 day 
co-culture of leukemic B cells with and without MSCs. 
On the basis of PARP cleavage we identified two different 
patterns: 1) one observed in a group of 15 patients in 
which leukemic B cells died following culture in medium 
alone, while they were rescued from apoptosis following 
culture with MSCs (the group was defined as “dependent” 
from microenvironment, Figure 2B, left panel); 2) a 
second pattern observed in a group of 12 CLL patients 
in which the addition of MSCs did not affect leukemic 
cell viability (the group defined “independent” from 
microenvironment, Figure 2B, right panel). We showed 
that this behaviour is not due to MSC features, since we 
did not find any differences using MSCs obtained from 
different patients (Figure 2C), while three different CLL 
clones exhibited different pattern of PARP cleavage in the 
presence of the same MSC line (completely abrogated in 
the first and second clone and still present in the third, 
Figure 2D). Finally, we correlated the 15 dependent and 
12 independent patients with some prognostic factors for 
CLL, such as IgVH mutational status, CD38 and ZAP70 
expression, and genomic aberrations (13q-, 17p-, 11q- 
deletion and 12+) (Figure S2). We did not observed any 
significant correlation between the different groups of 
patients. Clinical and biological features of patients are 
reported in Table 2.
Figure 1: MSCs protect CLL B cells from spontaneous apoptosis. A. Survival of CLL B cells cultured alone (n = 30), in presence 
of MSCs (n = 30) and of the stromal cell line HS-5 (n = 16). B. Survival of B cells from healthy donors cultured alone (n = 11), in presence 
of MSCs (n = 11) and HS-5 (n = 5). Viability was measured at the time point of 0, 3, 5 and 7 days by the Annexin V staining. Data are 
presented as mean ± standard deviation; paired Student’s t test; *p < 0.05, **p < 0.01, ***p < 0.001 and ****p < 0.0001.
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Figure 2: CLL B cell viability after 7 days of co-culture with MSCs. A. Leukemic B cell viability, assessed by flow cytometry 
using Annexin V staining, demonstrated a high heterogeneity in response to MSCs pro-survival stimuli. Student’s paired t test; p < 0.0001. 
B. The total cell lysates were subjected to SDS-PAGE, transferred to nitrocellulose membrane and detected with anti-PARP and anti-β-
actin. The figure shows a representative case of neoplastic B cells obtained from CLL patients (CLL#) co-cultured with MSCs (MSC#); 
CLL clones displaying the cleaved PARP after 7 days of culture, but showing the full length protein in presence of MSCs were classified 
as dependent (n = 15, left panel). CLL clones displaying the full length PARP with and without the presence of MSCs were classified as 
independent (n = 12, right panel). C. Representative cases of CLL B cells (CLL#) co-cultured with MSCs derived from different CLL 
patients (MSC#), demonstrating that neoplastic B cells present the same PARP pattern with different MSC lines. D. CLL B cells from 
distinct patients exposed to the effect of the same MSC line showed different degree of dependency to MSC pro-survival stimuli.
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Table 1: Clinical characteristics of CLL patients studied for MSCs isolation.
MSCs # RAI stage Age Sex  Bone marrow infiltration  (% Lymphocytes) CD19/5 (%)
#01 0 75 M 34 71
#02 1 65 M 70 92
#03 1 78 M 87 92
#04 0 66 F 70 83
#05 1 70 M 90 98
#06 3 75 M 40 68
#07 0 50 F 18 1
#08 0 49 M 56 72
#09 2 60 F 5 2
#10 2 72 M 75 46
#11 1 68 M 13 11
#12 2 61 M 26 54
#13 2 55 M 6 8
#14 0 51 M 54 86
#15 2 47 M 78 86
#16 2 59 F 19 34
#17 0 66 M 40 75
#18 0 54 M 42 68
#19 0 51 M 27 40
#20 1 48 M 47 83
#21 1 55 M 52 70
#22 1 55 M 18 60
#23 0 49 M 62 81
#24 1 69 M 56 50
#25 0 51 M 37 54
#26 1 66 M 64 70
#27 1 60 F 43 56
#28 0 60 M 37 54
#29 1 70 F 70 50
#30 1 63 M 43 70
#31 0 63 M 55 67
#32 1 60 M 40 43
#33 0 56 F 52 45
#34 0 71 F 25 22
#35 0 49 F 62 69
#36 0 60 M 75 85
#37 0 58 F 60 43
#38 3 59 F 50 77
#39 2 72 F 75 85
#40 2 55 M 17 35
#41 2 63 M 90 93
#42 0 56 F 32 50
#43 1 57 M 34 91
#44 0 52 M 21 44
#45 2 67 F 73 81
#46 1 56 F 40 48
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Table 2: Clinical characteristics of CLL patients.
CLL# Lymphocytes doubling time  RAI stage Cytogenetic1 IgVH mutational status (M/UM)2 ZAP703  CD384
#01 >6months 0 na M pos neg
#02 >6months 1 na M neg neh
#03 >6months 2 13q- M nd nd
#04 >6months 4 13q- UM pos pos
#05 >6months 1 na M nd pos
#06 >6months 1 11q- 12+ UM pos nd
#07 >6months 1 13q- UM neg pos
#08 >6months 2 na M nd nd
#09 >6months 2 17p- 13q- nd nd nd
#10 >6months 0 13q- M neg neg
#11 >6months 0 N UM pos neg
#12 >6months 0 13q- UM neg neg
#13 stable 1 13q- M pos neg
#14 >6months 2 na UM pos pos
#15 stable 0 13q- M pos neg
#16 <6months 1 12+ UM pos pos
#17 <6months 1 17p- UM neg nd
#18 >6months 4 17p- UM neg pos
#19 stable 1 13q- M nd nd
#20 stable 0 17p- 13q- M neg neg
#21 >6months 1 13q- M 0 neg
#22 stable 1 11q- 13q- 12+ UM pos pos
#23 na 1 na M na na
#24 >6months 1 11q- 12q- UM pos neg
#25 <6months 0 N UM pos neg
#26 >6months 1 N M pos neg
#27 stable 0 13q- UM pos neg
#28 stable 1 13q- M neg pos
#29 na 2 13q- UM pos pos
#30 na 0 13q- M pos pos
#31 stable 4 na M pos neg
#32 <6months 4 11q- UM pos neg
#33 stable 0 N UM pos neg
#34 stable 0 N M pos nd
#35 stable 1 13q- M pos neg
#36 stable 0 11q- 13q- 12+ UM pos pos
#37 <6months 1 11q- 12+ nd pos pos
#38 >12months 0 nd UM nd nd
#39 stable 1 13q- M pos neg
#40 <6months 2 11q- 13q- UM neg pos
#41 stable 1 13q- M neg neg
#42 na nd 13q- M neg neg
#43 nd nd 12+ na neg neg
#44 >6months 2 11q- UM neg pos
#45 na nd na na na pos
1 N = normal karyotype.
2 M=mutated, defined as having a frequency of mutations greater than 2% from germline VH sequence.
3 As determined by cytofluorymetric analysis (cut-off: 20%).
4 As determined by cytofluorymetric analysis (cut-off: 30%).
na= not available, nd=not determined
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MSCs affect CLL B cell behavior through the 
release of soluble factors and cell-cell contact
To discriminate between the role of cell-cell contact 
and soluble factors in the anti-apoptotic effect of MSCs, 
we cultured CLL B cells in direct contact to MSCs or in 
presence of MSCs separated by a porous transwell (TW) 
insert. After 7 days of culture, the viability of 12 CLL 
samples co-cultured with MSCs both in direct contact 
and following TW was 61.5%±18.3% and 47.5%±7.8% 
(p = 0.07), respectively, suggesting that both cell-contact 
and soluble factors contribute to the anti-apoptotic 
effect (Figure 3A). As cell migration is concerned, we 
demonstrated that the presence of MSC-conditioned 
medium (MSC-CM) significantly increases CLL B cell 
migration (651±543 migrated cells in medium alone vs 
2,809±1,318 migrated cells in MSC-CM, p < 0.0001) 
(Figure 3B). 
CLL B cells modulate the cytokine secretion 
profile of MSCs
In order to better define the signals exchanged 
between leukemic B cells and MSCs, a multiplex 
cytokine analysis was performed on supernatants obtained 
following culture of CLL B cells alone, MSCs alone and a 
combination of CLL B cell with MSCs. The quantification 
of the secretoma of MSCs and neoplastic B cells alone 
Figure 3: Effect of MSCs on CLL B cell viability and migration. A. Viability of leukemic B cells cultured alone (CLL), with 
MSCs in direct contact (CLL+MSCs) and in presence of a 0.4µm transwell system (CLL+MSC transwell) was assessed after 7 days by flow 
cytometry using Annexin V staining. Data are presented as mean ± standard deviation for 12 separated experiments; paired Student’s t test; 
****p < 0.0001. B. CLL B cells (n = 21) were allowed to migrate through a 3µm porous filter towards medium alone or MSC-conditioned 
medium for 3h; paired Student’s t test; ****p < 0.0001.
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is reported in Figure 4A and 4B, respectively. The CLL 
B cell/MSC co-cultures induce an increase (expressed as 
Fold Induction, FI) for most of the assessed molecules, 
being more evident for IL-8, CXCL10, CCL4 and CCL11. 
Particularly, these four molecules resulted up-regulated 
normalizing their concentration both on supernatant of 
MSCs alone (IL-8 10.6 FI, CCL4 148.6 FI, CCL11 6.7 FI 
and CXCL10 49.7 FI, Figure 4C) and on supernatant of 
CLL B cells alone (IL-8 5.8 FI, CCL4 1.8 FI, CCL11 6.9 
FI and CXCL10 4411 FI, Figure 4D). 
Interestingly, the above mentioned cytokines 
reached similar concentrations when the co-cultures were 
carried out in the presence of leukemic and normal B 
cells (Figure 5A). The only exception is represented by 
CXCL10, whose up-regulation was detected only during 
MSC/CLL B cell co-cultures, as confirmed by ELISA 
assay (Figure 5B). Finally, we tested the modulation of 
the secretion profile of leukemic B cells culture in the 
presence of MSC conditioned medium (MSC-CM) to 
assess how the factors released by MSCs can influence 
Figure 4: Cytokine/Chemokine secretion profile. A. MSCs and B. CLL B cells were cultured in medium alone for 7 days and the 
level of cytokines in supernatants was assessed by Bio-Plex (n = 11). Data are expressed as mean ± standard deviation of the concentration 
in pg/ml. C.-D. MSCs and CLL B cells were cultured in direct contact in complete medium for 7 days (n = 4). Cytokines/chemokines 
quantification in supernatants was normalized both on the levels observed in the media of MSCs cultured alone C. and of CLL B cells 
cultured alone D.. The co-culture induced a general modulation for most of C/C tested. Data are expressed as Fold Induction, FI.
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CLL B cell cito/chemokine production. We found that 
MSC supernatant induced an increase of different 
molecules, particularly IL-8 (27.4 FI), CCL4 (149 FI), 
CXCL10 (40 FI) and CCL5 (9.9) (Figure S3).
MSCs from CLL patients protect leukemic B 
cells after in vivo treatment with fludarabine and 
cyclophosphamide containing regimen
MSCs protect leukemic B cells from apoptosis 
induced in vitro by Fludarabine, Cyclophosphamide, 
Bendamustine, Prednisone and Hydrocortisone [28]. We 
Figure 5: Modulation of in vitro soluble factor production under different culture conditions. A. Quantification in 
supernatants was assessed by Bio-Plex; under co-culture conditions, IL-8, CCL4 and CCL11 reached a concentration higher than 
concentration detected in supernatant of the three single cell-population examined (MSCs, CLL and normal B cells; *p < 0.05, **p < 
0.01), but similar to the concentration detected co-culturing normal B cells in the presence of MSCs. On the contrary, CXCL10 production 
resulted high in supernatant of MSCs co-cultured with neoplastic B cells, but not with B cells from healthy subjects. B. MSCs were cultured 
in direct contact with CLL B cells in complete medium for 7 days (n = 7). CXCL10 quantification in supernatants was determined by ELISA 
assay. ANOVA test; *p < 0.05.
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used an in vitro co-culture system that employed leukemic 
B cells obtained from 10 CLL patients before and after 
one cycle of Fludarabine (FLU)/ Cyclophosphamide (Cy) 
therapy. As shown in Figure 6A, the presence of MSCs 
provide a significant protection from apoptosis in CLL B 
cells with respect to neoplastic cells cultured in medium 
alone; the viability ranged from 55.2%±18.2% with 
MSCs vs 9.4%±13.6% without MSCs, p < 0.0001, before 
in vivo treatment and from 34.2%±21.6% with MSCs vs 
13.1%±16.7% without MSCs, p < 0.0001, after in vivo 
therapy.
At the same time, we performed an in vitro parallel 
experiment assessing the MSC protective role on CLL 
cells exposed to the same compounds used for in vivo 
therapy. Leukemic B cells purified from 8 CLL untreated 
patients were pre-incubated for 3 and 12 hours with FLU 
and Cy and then cultured in the presence or absence of 
MSCs for 3, 5 and 7 days. Also in this case (Figure 6B), 
Figure 6: MSCs protect CLL B cells from in vivo drug-induced apoptosis. A. CLL B cells were collected before and at the 3rd 
day of the first in vivo treatment with FLU and Cy, according to the FLU-Cy protocol, and cultured in presence of MSCs (n = 10). Viability 
was measured at the time point of 3, 5 and 7 days by Annexin V staining. MSCs provided a significant level of protection from apoptosis in 
CLL B cells both pre- (left panel) and post-treatment with FLU-Cy (right panel) when compared to neoplastic B lymphocytes in medium 
alone. B. CLL B cells purified from 8 untreated patients were pre-treated for 3 hours (left panel) and 12 hours (right panel) with FLU-Cy or 
directly without pre-treatment C. and then cultured in the presence or absence of MSCs for 3, 5 and 7 days. MSCs preserved CLL B cells 
from in vitro drug-induced apoptosis. Data are presented as mean ± standard deviation; paired Student’s t test; *p < 0.05, **p < 0.01, ***p 
< 0.001, ****p < 0.0001.
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MSCs preserved CLL B cells from drug-induced apoptosis 
(after 3h pre-treatment and 7 day co-culture, neoplastic 
B cell viability, 27%±20% with MSCs vs 3.6%±3.4% 
without MSCs, p < 0.05; after 12h pre-treatment and 7 day 
co-culture, 25.1%±20.3% with MSCs vs 0.86%±0.69% 
without MSCs, p < 0.05). The same pattern was observed 
following co-culture of CLL B cells and MSCs with 
FLU+Cy for 3, 5 and 7 days without pre-treatment (after 7 
days, neoplastic B cell viability, 9.8%±4.5% with MSCs vs 
1.8%±1.3% without MSCs, p < 0.01) (Figure 6C).
MSCs from CLL patients do not protect leukemic 
B cells from apoptosis induced by kinase 
inhibitors
Previous studies [28, 29] and our data above 
reported demonstrated that MSCs can protect CLL B cells 
from drug-induced apoptosis. We next studied the effect 
of Bafetinib and Ibrutinib on the survival of neoplastic 
B cells obtained from 12 CLL patients cultured with and 
without MSCs. Leukemic B cell viability was assessed 
at 3, 5 and 7 days using Annexin V staining. We found 
that the presence of MSCs was not enough to inhibit 
Bafetinib and Ibrutinib induced apoptosis of neoplastic B 
cells (Figure 7A). In fact, after 7 day co-cultures, CLL B 
cell viability was 85.7%±4.1% in the absence of kinase 
inhibitors, 53.9%±17.2% in the presence of Bafetinib (p 
Figure 7: Kinase inhibitors counteract the MSC pro-survival effect. CLL B cells were cultured with MSCs in presence of 
Bafetinib and Ibrutinib. A. CLL B cells were co-cultured for 3, 5 and 7 days at the following conditions: medium alone, with the addition 
of 5µM Bafetinib and 5μM Ibrutinib. The graphs show the mean ± standard deviation of Annexin Vneg cells percentage of 12 separated 
experiments compared with untreated controls; paired Student’s  t test; ***p < 0.001; ****p < 0.0001. B. The total cell lysates (n = 10) were 
subjected to SDS-PAGE, transferred to nitrocellulose membrane and detected sequentially with: anti-PARP (row a), anti-Lyn-Tyr396(row 
b), anti-Lyn (row c), anti-ERK-Thr202/Tyr204 (row d), anti-ERK (row e) and anti-β-actin (row f). The figure shows a representative case 
of CLL B cells (CLL#) treated with 5µM Bafetinib and 5µM Ibrutinib and cultured with and without MSCs (MSC#).
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< 0.001), and 37.7%±14.7% with Ibrutinib (p < 0.0001). 
The data were also confirmed by western blotting analysis 
of PARP protein, indicating that, although the presence 
of MSCs, the addition of Bafetinib and Ibrutinib induced 
leukemic B cell in vitro apoptosis (Figure 7B, row a). To 
better understand the molecular mechanism by which 
the two inhibitors affect neoplastic B cell survival, we 
evaluated the phosphorylation status of Lyn (the tyrosine 
kinase that sustains the neoplastic clone survival through 
its constitutive activation) [30, 31] and ERK (a protein 
involved in BCR signaling, CXCL12/CXCR4 axis and 
responsible for the reduced apoptosis and the migration 
of CLL cells beneath stromal cells) [32]. We found 
that the treatment with Bafetinib considerably turns off 
Lyn phosphorylation at Tyr396 active site although the 
presence of MSCs; the same effect was also observed after 
treating CLL B cells with Ibrutinib (Figure 7B, row b). 
Both inhibitors are able to reduce ERK phosphorylation 
in leukemic B cells cultured with MSCs with respect to 
untreated controls (Figure 7B, row d). 
Moreover, we determined the effect of both kinase 
inhibitors on the survival of CLL B cells following 
engagement of BCR with anti-IgM. The pre-incubation 
of CLL B cells with Bafetinib and Ibrutinib reduced cell 
viability (Figure S4A); the latter data were confirmed by 
western blotting analyses of PARP, Lyn and ERK (Figure 
S4B).
In addition, on the base of the cleavage pattern 
of PARP protein, we divided the 12 patients treated 
with Bafetinib and Ibrutinib into “dependent” and 
“independent” groups showing no differences between 
the two groups on CLL B cell viability and Lyn as well 
as ERK de-phosphorylation (data not shown). This set 
of experiments suggest that kinase inhibitors mediated 
cytotoxicity independently from the protective effect of 
the microenvironment.
Bafetinib and Ibrutinib do not reduce neoplastic 
B cell migration to bone marrow stroma
By chemotaxis assay, we evaluated the effect of 
Bafetinib and Ibrutinib kinase inhibitors on the cross-
talking between CLL B cells and bone marrow MSCs. 
The pre-treatment of neoplastic B cells with Bafetinib 
and Ibrutinib did not inhibit the chemotaxis induced by 
MSC-CM and the number of migrated cells significantly 
increased with respect to basal migration (8,858±7,920 
Figure 8: MSC-conditioned medium preserves CLL B cell migration despite kinase inhibitors treatment. CLL B cells 
(n = 10) were pre-treated with 5µM Bafetinib and 5µM Ibrutinib for 1h and then allowed to migrate through a 3µm porous filter towards 
medium alone or MSC-conditioned medium for 3h; paired Student’s t test; **p < 0.01with respect to untreated cells.
Table 3: Expression level of chemokine receptors on CLL B cells.
no MSCs with MSCs
Alone 
(MFI)
Bafetinib 
(MFI)
Ibrutinib 
(MFI)
Alone 
(MFI)
Bafetinib 
(MFI) Ibrutinib (MFI)
CXCR4 19,880±4,858 28,568±5,563p < 0.01
24,442±6,105
ns 8,561±5,513
18,009±7,154
p < 0.0001
13,776±6,374
p < 0.0001
CCR7 5,085±1,308 3,475±988p < 0.05
4,498±890
p < 0.05 5,229±1,237
3,845±609
p < 0.001
4,904±1,040
ns
CXCR5 1,697±590 1,712±600ns
1,245±402
p < 0.01 1,623±507
1,621±466
ns
1,269±353
p < 0.05
CXCR3 3,969±2,635 2,379±1,721ns
2,366±1,704
ns 4,405±2,601
3,053±2,374
ns
2,841±1,994
ns
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alone vs 20,391±6,184 alone+MSC-CM, 19,517±7,931 
Bafetinib+MSC-CM and 18,772±10,094 Ibrutinib+MSC-
CM; p < 0.01, Figure 8). 
Interactions between chemokines and their receptors 
mediate cell migration. CLL B cells express high levels of 
CXCR4, CCR7, CXCR5 and CXCR3 chemokine receptors 
[33, 34]. We investigated whether kinase inhibitors 
regulate chemokine receptor expression on neoplastic B 
cells cultured in the presence and absence of MSCs. The 
two kinase inhibitors affect receptor expression in different 
ways (Figure S5). In particular, CXCR4 was increased by 
the treatment with Bafetinib and Ibrutinib, while CCR7 
was reduced by Bafetinib; at the same time, CXCR5 was 
affected only by Ibrutinib and the two kinase inhibitors do 
not show a significant influence on CXCR3 expression, 
suggesting that their action may be carried out mostly by 
the receptors involved in the process of CLL homing. The 
data are expressed as MFI and summarized in Table 3. 
Bafetinib and Ibrutinib inhibit 
pseudoemperipolesis in CLL B cell/MSC co-
cultures in a CD49d-dependent way
We evaluated the ability of neoplastic B cells 
to migrate and adhere beneath MSCs after treatment 
Figure 9: Reduction of spontaneous migration of CLL B cells beneath MSCs (pseudoemperipolesis) and CD49d 
surface expression. A. CLL B cells were pre-treated for 1h with 5µM Bafetinib and Ibrutinib and seeded onto confluent marrow stromal 
cell layers. After overnight incubation, the CLL cells that did not migrated into the stromal cell layer were washed off. Graph represents the 
mean ± standard deviation of the percentage of migrated CLL cells from 7 different patients; paired Student’s t test; *p < 0.05, **p < 0.01. 
B. Representative phase-contrast photomicrographs of pseudoemperipolesis of untreated CLL B cells (alone) and, in comparison, reduced 
pseudoemperipolesis of the same CLL sample pre-treated with Bafetinib and Ibrutinib (20X magnification, Olympus IX81). C. Malignant 
B cells (n = 7) were cultured alone or with MSCs for 24h and CD49d expression level was assessed by flow cytometry. Data are presented 
as the ratio of the mean ± standard deviation of MFI; paired Student’s t test; **p < 0.01 with respect to untreated cells.
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with Bafetinib and Ibrutinib. We found that the two 
inhibitors were able to significantly reduce CLL B cell 
pseudoemperipolesis. In fact, the percentage of neoplastic 
B cells adherent to the stromal layer was 7.7%±3.8% in 
the absence of inhibitors, 2.5%±3.0% with Bafetinib (p 
< 0.01), and 3.3%±2.4% with Ibrutinib (p < 0.05) (Figure 
9A). The phase-contrast photomicrographs displayed in 
Figure 9B illustrate the effect of the pre-treatment of CLL 
B cells with the two molecules, highlighting a marked 
reduction of neoplastic cell adhesion to the MSC layer 
in the presence of inhibitors as compared to untreated 
controls (alone). Since CD49d plays a critical role in cell 
adhesion and increases the ability of malignant cells to 
access to protective niches [35], we addressed the effect of 
the two kinase inhibitors on its expression on CLL B cell 
surface, demonstrating that the treatment with Bafetinib 
and Ibrutinib significantly decreases CD49d expression in 
co-culture with MSCs (MFI ratio 0.87±0.12 Bafetinib, p 
< 0.05, and 0.89±0.05 Ibrutinib, p < 0.01) (Figure 9C).
DISCUSSION
In this study MSCs from bone marrow of 46 CLL 
patients, co-cultured to mimic the neoplastic in vivo 
microenvironment, were isolated and characterized. We 
demonstrated that MSCs support in vitro leukemic B cell 
survival more efficiently than the stromal cell line HS-5 
[36]. In the last years, several studies tried to elucidate the 
role of stromal cells in CLL B cell survival, and primary 
bone marrow stromal cells have been shown to be effective 
in inhibiting apoptosis of cultured CLL [37] and acute 
lymphocytic leukemia (B-ALL) cells [38]. In these reports, 
the in vitro co-culture systems used were represented by 
layers of marrow cells, including fibroblasts, macrophages 
and fat cells, or layers of immortalized cell lines, but not 
from a selected and well defined cell population. 
Our data show that CLL B cells are susceptible to 
the anti-apoptotic effect of MSCs, favoring neoplastic B 
cell survival in vitro for at least 7 days. These results are 
noteworthy considering that CLL B cells spontaneously 
undergo apoptosis once they have been removed from 
the in vivo microenvironment and placed in suspension 
cultures without supportive stroma. Despite CLL 
B cells display typical phenotype and cytogenetic 
abnormalities, the disease is quite heterogeneous in terms 
of clinical courses, suggesting that each leukemic clone 
is characterized by intrinsic features that might affect the 
interactions with the surrounding environment. In this 
context, we found a great variability in CLL cells survival 
when co-cultured with MSCs, since the fraction of living 
leukemic B cells ranged from 40% to 76%. The analysis 
of the cleavage pattern of PARP protein detected in CLL 
patients after 7 day co-culture with MSCs allowed us to 
distinguish patients into two groups on the basis of their 
dependence/independence to microenvironmental pro-
survival stimuli. The first group is represented by those 
CLL B cell samples that underwent spontaneous apoptosis 
in medium alone, but were rescued from apoptosis 
following exposure to MSCs. On the contrary, the second 
group identified CLL samples whose viability was high 
when cultured both in medium alone and in the presence 
of MSCs, indicating that these CLL clones were able 
to survive independently from signals coming from the 
microenvironment. In terms of survival, we observed that 
each CLL clone responded in the same manner to different 
MSCs samples, suggesting that the heterogeneity of 
leukemic clones is likely to be related to intrinsic features 
of leukemic B cells rather than to external stimuli.
The increase of leukemic B cell survival in the 
presence of MSCs might be mediated by soluble factors 
and/or cell-cell contact. Our results demonstrated that both 
soluble factors and cell-cell contacts are able to support 
neoplastic B cell viability. Survival factors counteracting 
in vitro apoptosis of CLL B cells have been reported 
in the past [13, 39], but the humoral/cellular factors 
responsible for the pro-survival effect in vivo had not been 
yet identified. By a multiplex cytokine assay, we found 
that the MSC/leukemic cell co-culture system induced 
an increase for many of the cytokines/chemokines tested, 
the strongest being represented by IL-8, CCL4, CCL11 
and CXCL10. Although the involvement of IL-8 and 
CCL4 in CLL leukemic cell survival and growth has been 
already reported in the literature [40-44], our findings 
confirm these data and extend the observations on CCL11 
and CXCL10 production. In particular, the addition of 
MSCs to leukemic B cells up-regulates the level of these 
two molecules. Regarding CCL11, this effect is not a 
peculiar finding in malignant B cells since normal B cells 
showed the same pattern of secretion; more interestingly, 
CXCL10 is exclusively produced when MSCs were co-
cultured with malignant B cells but not with normal B 
lymphocytes, supporting a key role for this chemokine in 
CLL progression. The basal production of CXCL10, in 
fact, was very low in the supernatants of CLL leukemic 
B cells and of MSCs cultured alone, while we found a 
marked increase after co-culture. In light of the fact that 
CXCL10 receptor, CXCR3, is constitutively expressed on 
CLL B cell surface [33], these data stress the importance 
of the interconnection between chemokine receptor 
signaling and stimuli coming from the microenvironment.
Furthermore, we demonstrated that MSCs were 
able to rescue leukemic B cells from apoptosis also when 
they have been previously exposed to in vivo Fludarabine 
(FLU) and Cyclophosphamide (Cy) containing 
regimen. These data point out the protective role of 
microenvironment, not only toward neoplastic in vitro B 
cells [28], but also on apoptosis induced by the in vivo 
administration of the chemotherapy.
In the last few years, the observation of the key role 
of tumor microenvironment and immune dysfunctions 
in leukemic cells accumulation prompted the use of a 
number of compounds targeting CLL microenvironment. 
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Different drugs used for CLL treatment have been 
demonstrated to induce in vitro apoptosis of CLL B cells 
whereas their effect is reduced when administered in vivo, 
probably related to the presence of pro-survival stimuli 
coming from surrounding environment. Therefore, it is 
mandatory to test the effect of new therapeutic agents 
in the presence of microenvironmental partners (such as 
MSCs) which might interfere with the biological effects 
of the drug, allowing the identification of subgroups of 
patients who may benefit from treatments targeting the 
cross-talk with supportive cells at the sites of the disease. 
For this reason, we tested in our co-culture system the 
effect of inhibitors targeting different kinases involved 
in BCR pathway, such as Bafetinib and Ibrutinib, the 
latter known to reduce CLL B cell migration and to 
induce in vitro apoptosis [23, 45]. We found that both 
Bafetinib and Ibrutinib were able to induce leukemic cell 
apoptosis independently from MSCs presence, through a 
mechanism involving a de-phosphorylation of Lyn and 
ERK kinases, two relevant proteins in CLL pathogenesis. 
In contrast, these inhibitors did not affect B cell migration 
toward MSC-conditioned medium, rich in cytokines and 
chemokines, suggesting that these cells do not lose their 
ability to move toward a protective niche. Migration is 
mediated by the interaction between chemokines and their 
receptors, i.e. CXCR4, CCR7, CXCR5 and CXCR3, these 
latter being overexpressed on CLL B cells [33, 34]. In this 
work, we observed that, in malignant B cells co-cultured 
with MSCs, Bafetinib significantly decreased CCR7 
expression, involved in lymphocyte entry the lymph node, 
and up-regulated CXCR4 which, instead, is engaged in the 
trafficking in lymphoid organs. CXCR4 up-regulation was 
also observed following in vitro treatment with Ibrutinib. 
Although it still remains unknown the exact mechanism 
of CXCR4 up-regulation, we found that the use of kinase 
inhibitors induced modifications in chemokine receptors. 
Since cell-cell contact with stromal cells is crucial for 
CLL B cell survival, we tested the effect of Bafetinib and 
Ibrutinib on neoplastic B cell adhesion to an MSC layer 
finding a significant reduction of cell adhesion through a 
down-modulation of CD49d expression. Taking together, 
these results suggest that Bafetinib and Ibrutinib not 
only are able to reduce CLL B cell viability by blocking 
molecules important for cell survival, but they could 
interfere with the interactions between chemokines and 
their receptors and with cell-cell contact.
In conclusion, this study demonstrates that MSCs 
co-culture represents a reproducible in vitro system with 
functional similarities to in vivo bone marrow conditions, 
pointing out that the heterogeneity of the disease is 
reflected also in CLL B cell capacity to respond to 
favorable signals from MSCs. Moreover, as a result of the 
ability of kinase inhibitors to inactivate enzymes in the 
BCR signaling pathway, which are aberrantly activated 
in CLL, leukemic B cells lose not only their ability 
to proliferate and survive but also to interact with the 
protective bone marrow microenvironment, a necessary 
condition to aim the eradication of the disease. In addition, 
for the first time, we herein demonstrated that Bafetinib 
presents a mechanism of action quite similar to that of 
Ibrutinib in blocking CLL B cell-MSC cross-talk. Our 
findings on the role of MSCs and their effect on neoplastic 
B lymphocytes open a new scenario to better identify the 
most effective drugs or drug combinations targeting the 
pro-survival cross-talk between neoplastic B cells and 
marrow elements. 
MATERIALS AND METHODS
Ethic statement
Primary CLL samples were obtained after informed 
consent according to the Declaration of Helsinki. The ethic 
approval for our study was obtained from the local ethic 
committee of “Regione Veneto on chronic lymphocytic 
leukemia”.
Mesenchymal stromal cell long-term cultures
Mesenchymal stromal cells (MSCs) were isolated 
from iliac crest bone marrow (BM) aspirate of 46 CLL 
patients (Table 1) under local anesthesia and diluted 1:3 in 
Phosphate Buffered Saline (PBS1X) (Euroclone; Milan, 
Italy). BM mononuclear cells (BMMCs) were isolated by 
F/H (Amersham Biosciences) centrifugation and plated 
at density 1,000cells/cm2 in Dulbecco’s modified Eagle’s 
medium (DMEM) (Euroclone) with 1,000mg/ml glucose, 
L-glutamine, 10% heated inactivated fetal bovine serum 
(FBS) and 100U/ml Penicillin, 100µg/ml Streptomicin 
(Life Technologies; Paisley, UK). BMMC suspensions 
were incubated at 37°C in humidified atmosphere 
containing 5% CO2 and allowed to attach for 7 days; at 
this time-point, non-adherent fraction was discarded and 
adherent cells were fed every week with fresh medium. 
These cells were maintained until confluence, then they 
were removed by Accutase (Sigma-Aldrich; Milan, Italy), 
centrifuged and diluted 1:3 for subsequent expansion in 
25cm3 flasks or cryopreserved for future uses.
Human primary samples
Peripheral blood mononuclear cells (PBMCs) 
were obtained from heparinised venous blood of 45 CLL 
patients (Table 2) and 11 normal donors, representative of 
the adult healthy population. PBMCs of the patients were 
isolated by density-gradient centrifugation over Ficoll-
Hypaque (F/H; Amersham Biosciences; Buckinghamshire, 
UK). Where necessary, further purifications were 
performed. Finally all the samples utilized had a content 
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of neoplastic B cells greater than 95%. Untouched 
peripheral blood B cells from normal donors were 
isolated using the RosetteSep isolation kit for B cells 
(STEMCELL Technologies; Vancouver, Canada). The 
purity of the obtained peripheral blood cells was at least 
95% (CD19+), as assessed by flow cytometry. All patients 
had a confirmed diagnosis of CLL by NCI Working Group 
Definition [46] and were classified according to the Rai 
staging system [47]. 
Culture conditions
Purified leukemic and normal B cells (2x106/ml) 
and MSCs (1x105/well seeded into 12 well plates) were 
cultured in complete RPMI-1640 medium (Sigma-Aldrich) 
at 37°C in a humidified atmosphere containing 5% CO2. 
For co-culture experiments, neoplastic and normal B 
cells were added to MSC layer at 20:1 ratio in complete 
RPMI-1640 medium. The plates were incubated at 37°C, 
in a humidified atmosphere containing 5% CO2 and B 
lymphocytes were harvested after 3, 5 and 7 days. In some 
experiments, B cells obtained from 10 CLL patients before 
and after therapy according to the protocol FLU-Cy: FLU 
25 mg/m2 for 3 days and Cy 350 mg/m2 for 3 days, every 
28 days; this therapy is the standard of care for patients 
needing a therapy. For in vitro treatment with FLU and Cy, 
CLL B cells were incubated with 20µM FLU and 5mM Cy, 
as previously described [48]. For experiments using kinase 
inhibitors, CLL B cells were cultured in presence and 
absence of MSCs, as previously described, adding 5µM 
Bafetinib (Selleck Chemicals; Munich, Germany), 5µM 
Ibrutinib (Selleck Chemicals), and/or goat F(ab’)2 anti-
human IgM (10µg/ml) (Southern Biotech; Birmingham, 
USA). The concentration of inhibitors is chosen according 
to preliminary experiments with different doses. In some 
experiments, we also employed the HS-5 cell line, a 
human fibroblastoid cell line available from the American 
Type Culture Collection (ATCC; Manassas, VA), which 
represent a component of the marrow microenvironment 
[49]. To achieve complete confluence and the formation of 
a stable feeder monolayer, 1x105 HS-5 cells were plated 
in 12 well plates and irradiated at 4,000 Rad x 15 minutes 
at least 48-72 hours before the addition of leukemic B 
cells. Transwell (TW) experiments, using polycarbonate 
membranes (Corning Costar; Cambridge, UK) with 0.4µm 
pores, were performed to prevent physical contact between 
B lymphocytes and MSCs, allowing the diffusion of 
soluble factors secreted by the adherent layers of stromal 
cells.
Cell viability testing
Freshly isolated CLL B and normal B cells were 
cultured in direct or indirect (TW) contact with MSCs and 
HS-5 at a ratio of 20:1. MSCs and HS-5 were cultured 
in 12 well plate with DMEM until confluence and then 
placed in RPMI medium (Euroclone), prior the addiction 
of B lymphocytes. Leukemic cells were collected after 
3, 5 and 7 days, leaving intact the adherent layer, and 
examined for apoptosis status by staining with Annexin 
V-FITC accordingly to the manufacturer’s instructions 
(Immunostep; Salamanca, Spain). Briefly, aliquots of 
5x105 cells were harvested, washed and incubated for 
10 minutes in the dark and at RT with anti-CD19 APC 
(Invitrogen). Then, cells were washed and 100μl of 
binding buffer plus 5μl of Annexin V-FITC were added 
for further 10 minutes in the dark and at RT. After the 
incubation, 100μl of binding buffer were added and 
cells were analyzed by flow cytometer FACSCalibur. At 
least 20,000 events were collected using CellQuestPRO 
software. 
Multiplex cytokine analysis
In order to quantify chemokines and cytokines 
released in culture supernatants, cell-free culture media 
of previous experiments were collected after 7 days for 
the human Bio-Plex™ 27 plex Cytokine Assay (Bio-Rad 
Laboratories; Hercules, CA), which enables the detection 
of Interleukin-1β (IL-1 β), IL-1ra, IL-2, IL-4, IL-5, IL-6, 
IL-7, IL-8, IL-9, IL-10, IL-12 (p70), IL-13, IL-15, IL-17, 
Basic FGF, CCL11, G-CSF, GM-CSF, IFN-γ, CXCL10 
(IP-10), CCL2 (MCP-1), CCL3 (MIP-1α), CCL4 (MIP-
1β), PDGF-BB, CCL5, TNF-α and VEGF. Measurements 
were performed on Bio-Plex in duplicates. The Bio-Plex 
Manager™ software shows data as Median Fluorescence 
Intensity (MFI) as well as concentration (pg/ml). The 
concentration of the analyte bound to each bead is 
proportional to the MFI of reporter signals.
ELISA assay
The cell-free culture media of previous experiments 
were collected after 7 days and analyzed for CXCL10 by 
ELISA (R&D Systems, Minneapolis, MN) according to 
the manufacturer’s instructions. 
Western blotting
B cells (5x105 for each assay) were processed as 
previously explained [48]. Samples were then subjected 
to SDS/PAGE (10% gels), transferred to nitrocellulose 
membranes and immunostained with primary antibodies 
to: PARP (Cell Signaling Technology Inc.), Lyn (Santa 
Cruz), Lyn-Tyr396 (Epitomics Onc.; Burlingame, CA), 
ERK (Cell Signaling Technology Inc.), ERK-Thr202/
Tyr204 (Cell Signaling Technology Inc.), β-actin (Sigma-
Aldrich), using an enhanced chemiluminescent detection 
system (Pierce; Rockford, IL).
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Flow cytometry analysis
Freshly isolated CLL B cells were cultured with 
and without MSCs and treated with 5µM kinase inhibitors 
as above described. Cells (5x105 for each assay) were 
collected after 48h, leaving intact the adherent layer, and 
stained with anti-CD49d PE (BD Biosciences), anti-CCR7 
FITC (R&D Systems Inc., Minneapolis, MN, USA), anti-
CXCR4 PE (R&D Systems Inc.) anti-CXCR3 PE-Cy5.5 
(BD Biosciences, Franklin Lakes, NJ, USA), anti-CXCR5 
FITC (R&D Systems Inc.), and anti-CD19 APC (BD 
Biosciences) monoclonal antibodies. Cells were washed 
with PBS1X and incubated with saturating concentrations 
of the appropriate antibodies for 15 minutes at room 
temperature. 20,000 total events were acquired using 
FACSCanto A (Becton Dickinson) and the data were 
analysed by FACSDiva 7 software. Samples were gated 
on intact cells by forward scatter (FSC) vs side scatter 
(SSC). For analysis, a second gating step on CD19+ cells 
was used. Here, we used a difference between the Mean 
Fluorescence Intensity (MFI) of fully-stained samples and 
the Fluorescence Minus One (FMO) controls.
Chemotaxis assay
To obtain the MSC-conditioned medium (MSC-
CM), MSCs were cultured for 48h in complete RPMI-
1640 medium (Sigma-Aldrich) at 37°C in a humidified 
atmosphere containing 5% CO2. The migration of 
pretreated CLL B cells in response to MSC-CM was 
evaluated using 12-well Corning chemotaxis chamber 
(Corning Life Sciences; Acton, MA). Briefly, 2.5x106 
cells were incubated in 0.5ml RPMI medium with and 
without kinase inhibitors for 1h at 37°C. Then, cells were 
transferred into the top chambers of transwell culture 
insert with a pore size of 3µm. Filters were then placed 
onto wells containing complete RPMI medium or MSC-
CM, and CLL B cells were allowed to migrate for 3h at 
37°C. Migrated cells in the lower chamber were then 
collected and counted on a FACSCanto A for 60 seconds 
in triplicates. 
Migration assay evaluating CLL 
pseudoemperipolesis
Pseudoemperipolesis is an in vitro phenomenon in 
which CLL cells spontaneously migrate beneath marrow 
stromal cells to mimic the in vivo migration and homing 
to stromal cells in the tissues [50]. Briefly, MSCs were 
seeded onto 12-well plates in complete RPMI medium till 
confluence. CLL B cells were suspended to a concentration 
of 2x106 cells/ml in complete RPMI medium with or 
without 5µM Bafetinib, CAL-101 and Ibrutinib and 
incubated for 1h at 37°C in 5% CO2 in complete RPMI 
medium. After incubation, CLL cells were added to the 
MSC layers and the plates were incubated at 37°C in 5% 
CO2 overnight. Cells that had not migrated into the stromal 
cell layer were removed by vigorously washing 3 times 
with RPMI 1640 medium. The complete removal of non-
migrated cells and the integrity of the stromal cell layer 
containing transmigrated cells were assessed by phase-
contrast microscopy and documented photographically. 
The stromal cell layer containing transmigrated cells was 
detached by incubation with Accutase (Sigma-Aldrich). 
Cells were stained with anti-CD19 APC to exclude MSCs 
and counted by flow cytometry. 
Statistical analysis
Statistical analysis was performed using Student’s t 
test, Fisher’s exact test and ANOVA test. Data are reported 
as median ± standard deviation (SD) and a p-value of 0.05 
or less was considered as significant. 
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